![]() |
Market Research Report
Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2016 |
||||||
Published by | Global Markets Direct | Product code | 200950 | ||||
Published | Content info | 62 Pages Delivery time: 1-2 business days |
|||||
Price |
|
Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2016 | ||
Published: October 29, 2016 | Content info: 62 Pages |
|
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Warts - Pipeline Review, H2 2016, provides an overview of the Genital Warts (Infectious Disease) pipeline landscape.
Genital warts (condyloma acuminata) are one of the most common types of sexually transmitted infections. Genital warts are caused by the human papillomavirus (HPV). Symptoms include small, flesh-colored or gray swellings in genital area, itching or discomfort in genital area, pain during intercourse and frequent urination. Treatment includes antiviral drugs and surgery.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Warts - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Genital Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Genital Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Warts (Condylomata Acuminata) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 8, 1, 4 and 2 respectively for Genital Warts.
Genital Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.